TRIM17 increases α-synuclein expression by inhibiting ubiquitination/degradation of the transcription factor ZSCAN21 mediated by TRIM41.
The aim is to assess:
- The role of this pathway in Parkinson’s disease models;
- The impact of TRIM41 and ZSCAN21 mutations identified in patients;
- The molecular mechanisms of TRIM41 inhibition by TRIM17.